{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:05:02Z","timestamp":1780607102810,"version":"3.54.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic nephrotic syndrome is the most common glomerulopathy in children, and minimal change disease (MCD) is the most common histological pattern. First-line treatment involves glucocorticosteroids, but frequent relapses and steroid dependence may lead to steroid-related complications. Rituximab (RTX) is recommended in cases of lack of response or treatment side effects, reducing relapse rates and limiting the need for other medications. The mechanism of RTX involves B-cell depletion through various cytotoxic mechanisms. Its efficacy in nephrotic syndrome (NS) may stem from its influence on cytokines produced by B cells and a further effect on the podocyte cytoskeleton has been postulated. The present case describes a 19-year-old male with NS resulting from MCD, with a frequently relapsing, steroid-dependent, multidrug-resistant disease.\u00a0He experienced a hypersensitivity reaction to RTX after the third dose, which contraindicated therapy continuation with traditional infusion. Due to the limited therapeutic options, a 12-step RTX desensitization protocol was adopted, allowing for safe administration of subsequent doses, achievement of remission, and gradual discontinuation of glucocorticosteroids.<\/jats:p>","DOI":"10.1093\/joneph\/aajaf023","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:15:56Z","timestamp":1775067356000},"page":"188-191","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab in a desensitization protocol as a rescue therapy in severe nephrotic syndrome\u2014a case report"],"prefix":"10.1093","volume":"39","author":[{"given":"Agata","family":"Bukowska","sequence":"first","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-9872","authenticated-orcid":false,"given":"Aleksandra","family":"Rymarz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4117-7249","authenticated-orcid":false,"given":"Filip","family":"Wantoch-Rekowski","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0176-9845","authenticated-orcid":false,"given":"Beata","family":"Bienia\u015b","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Medical University of Lublin , Lublin ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-8171","authenticated-orcid":false,"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2026060416364281300_aajaf023-B1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"key":"2026060416364281300_aajaf023-B2","doi-asserted-by":"publisher","year":"2024","DOI":"10.1016\/j.kint.2024.11.007"},{"key":"2026060416364281300_aajaf023-B3","doi-asserted-by":"publisher","year":"2021","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"2026060416364281300_aajaf023-B4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/cjn.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"2026060416364281300_aajaf023-B5","doi-asserted-by":"publisher","first-page":"823204","DOI":"10.3389\/fimmu.2022.823204","article-title":"B-cell dysregulation in idiopathic nephrotic syndrome: what we know and what we need to discover","volume":"13","author":"Colucci","year":"2022","journal-title":"Front Immunol"},{"key":"2026060416364281300_aajaf023-B6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"key":"2026060416364281300_aajaf023-B7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12016-016-8556-5","article-title":"Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies","volume":"54","author":"Bonamichi-Santos","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026060416364281300_aajaf023-B8","doi-asserted-by":"publisher","first-page":"e12397","DOI":"10.1002\/clt2.12397","article-title":"Retrospective analysis of rapid drug desensitization with biologic agents: a single center experience","volume":"14","author":"Unutmaz Erkaya","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"2026060416364281300_aajaf023-B9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00467-018-3900-z","article-title":"Infusion reactions associated with rituximab treatment for childhood-onset \u00adcomplicated nephrotic syndrome","volume":"33","author":"Kamei","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2026060416364281300_aajaf023-B10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2026060416364281300_aajaf023-B11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.currproblcancer.2017.07.003","article-title":"Rituximab desensitization in 3 patients with severe rituximab allergy","volume":"41","author":"\u00d6zt\u00fcrk","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"2026060416364281300_aajaf023-B12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/1078155220948596","article-title":"Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis","volume":"27","author":"Villarreal-Gonz\u00e1lez","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2026060416364281300_aajaf023-B13","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.5415\/apallergy.2021.11.e37","article-title":"Successful desensitization to high dose rituximab for a child with nephrotic syndrome\u2014the first report in the literature","volume":"11","author":"Kakleas","year":"2021","journal-title":"Asia Pac Allergy"},{"key":"2026060416364281300_aajaf023-B14","doi-asserted-by":"publisher","first-page":"SD01","DOI":"10.7860\/JCDR\/2019\/38080.12821","article-title":"Successful rapid desensitization of 2 teenagers with rituximab hypersensitivity","volume":"13","author":"Cansever","year":"2019","journal-title":"J Clin Diagn Res"},{"key":"2026060416364281300_aajaf023-B15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaci.2013.02.004","article-title":"Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: increase in number of Treg cells after desensitization","volume":"132","author":"Aydogan","year":"2013","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/1\/188\/67716646\/aajaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/1\/188\/67716646\/aajaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:36:49Z","timestamp":1780605409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/1\/188\/8571496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajaf023","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]}}}